Structure Therapeutics (GPCR) Competitors $37.69 +1.32 (+3.63%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GPCR vs. ASND, MDGL, JAZZ, VKTX, LEGN, ELAN, CYTK, GRFS, BPMC, and NUVLShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Ascendis Pharma A/S (ASND), Madrigal Pharmaceuticals (MDGL), Jazz Pharmaceuticals (JAZZ), Viking Therapeutics (VKTX), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Grifols (GRFS), Blueprint Medicines (BPMC), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry. Structure Therapeutics vs. Ascendis Pharma A/S Madrigal Pharmaceuticals Jazz Pharmaceuticals Viking Therapeutics Legend Biotech Elanco Animal Health Cytokinetics Grifols Blueprint Medicines Nuvalent Ascendis Pharma A/S (NASDAQ:ASND) and Structure Therapeutics (NASDAQ:GPCR) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Which has more risk and volatility, ASND or GPCR? Ascendis Pharma A/S has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -3.23, meaning that its share price is 423% less volatile than the S&P 500. Does the media prefer ASND or GPCR? In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Structure Therapeutics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 6 mentions for Structure Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.73 beat Structure Therapeutics' score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ASND or GPCR? Ascendis Pharma A/S received 408 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Structure Therapeutics an outperform vote while only 66.36% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformAscendis Pharma A/SOutperform Votes43466.36% Underperform Votes22033.64% Structure TherapeuticsOutperform Votes2686.67% Underperform Votes413.33% Which has stronger valuation and earnings, ASND or GPCR? Structure Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Structure Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$288.08M26.53-$521.07M-$9.31-13.54Structure TherapeuticsN/AN/A-$89.62M-$0.75-48.49 Do analysts prefer ASND or GPCR? Ascendis Pharma A/S presently has a consensus target price of $195.92, indicating a potential upside of 55.46%. Structure Therapeutics has a consensus target price of $86.80, indicating a potential upside of 138.66%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.00Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ASND or GPCR? 91.8% of Structure Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ASND or GPCR more profitable? Structure Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -154.18%. Ascendis Pharma A/S's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-154.18% N/A -59.81% Structure Therapeutics N/A -20.12%-19.11% SummaryAscendis Pharma A/S beats Structure Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.08B$6.77B$5.22B$8.94BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-48.499.10124.8816.69Price / SalesN/A391.951,276.9391.02Price / CashN/A49.2238.8936.42Price / Book3.729.286.395.98Net Income-$89.62M$154.14M$118.47M$225.08M7 Day Performance-5.16%-3.66%-1.94%-0.37%1 Month Performance-0.68%5.77%2.65%4.23%1 Year Performance-32.13%38.38%36.44%27.64% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.2484 of 5 stars$37.69+3.6%$86.80+130.3%-33.5%$2.16BN/A-50.25136News CoverageASNDAscendis Pharma A/S3.3268 of 5 stars$124.33-1.8%N/A+40.9%$7.84B$288.08M-13.35640Analyst DowngradeShort Interest ↑News CoverageMDGLMadrigal Pharmaceuticals4.4038 of 5 stars$350.70-1.2%N/A+115.9%$7.65B$76.81M-13.9890Positive NewsJAZZJazz Pharmaceuticals4.8951 of 5 stars$123.61+3.8%N/A+4.6%$7.63B$3.83B17.412,800Insider SellingGap UpVKTXViking Therapeutics4.5202 of 5 stars$68.48-0.5%N/A+454.5%$7.63BN/A-73.6320LEGNLegend Biotech1.9418 of 5 stars$40.03-2.2%N/A-39.1%$7.30B$285.14M-51.321,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionELANElanco Animal Health3.6676 of 5 stars$14.07-3.0%N/A+34.5%$6.96B$4.42B-5.529,300Earnings ReportShort Interest ↑Analyst RevisionCYTKCytokinetics4.0784 of 5 stars$57.98+3.8%N/A+74.8%$6.53B$7.53M-10.78250Insider SellingAnalyst RevisionGRFSGrifols1.4785 of 5 stars$9.49-0.1%N/A+2.2%$6.52B$6.81B0.0023,737Gap UpHigh Trading VolumeBPMCBlueprint Medicines2.0018 of 5 stars$100.83-0.6%N/A+64.6%$6.33B$249.38M-47.79640Analyst ForecastShort Interest ↑Gap UpNUVLNuvalent2.2591 of 5 stars$95.42+1.4%N/A+58.8%$6.18BN/A-34.3240Earnings ReportAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Madrigal Pharmaceuticals Alternatives Jazz Pharmaceuticals Alternatives Viking Therapeutics Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Grifols Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GPCR) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts